Inovio Confirms Frontrunner Status In COVID-19 Vaccine Race, But Can It Prove Skeptics Wrong?
Interview: CEO Says He Welcomes Scrutiny, Competition
Executive Summary
Its ‘virus chasing’ habits has given Inovio a bad reputation. But with backing from CEPI and Bill Gates, it has a chance to prove the doubters wrong.
You may also be interested in...
Coronavirus Update: AZ Gets $1bn From US, Secures Capacity For One Billion Vaccine Doses
Inovio vaccine data published, US government invests to protect, generic remdesivir launched in Bangladesh.
Coronavirus Update: Sanofi And GSK Unveil 'Unprecedented' Vaccine Alliance
Plus: Lilly unveils Olumiant COVID-19 study, Samsung and Vir to collaborate on antibody, Korean industry asks for government assistance.
Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus
Pfizer is up against AstraZeneca and Sanofi in developing competing approaches to tackling the unmet need in respiratory syncytial virus (RSV). But earlier failures mean all players will need much more data to sway regulators.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports